These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10398279)

  • 1. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
    Nastiuk KL; Mansukhani M; Terry MB; Kularatne P; Rubin MA; Melamed J; Gammon MD; Ittmann M; Krolewski JJ
    Prostate; 1999 Aug; 40(3):172-7. PubMed ID: 10398279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
    Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
    N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
    Wilkens EP; Freije D; Xu J; Nusskern DR; Suzuki H; Isaacs SD; Wiley K; Bujnovsky P; Meyers DA; Walsh PC; Isaacs WB
    Prostate; 1999 Jun; 39(4):280-4. PubMed ID: 10344217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
    Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.
    Fodor FH; Weston A; Bleiweiss IJ; McCurdy LD; Walsh MM; Tartter PI; Brower ST; Eng CM
    Am J Hum Genet; 1998 Jul; 63(1):45-51. PubMed ID: 9634504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
    Gotlieb WH; Friedman E; Bar-Sade RB; Kruglikova A; Hirsh-Yechezkel G; Modan B; Inbar M; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
    J Natl Cancer Inst; 1998 Jul; 90(13):995-1000. PubMed ID: 9665148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
    Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
    Krainer M; Silva-Arrieta S; FitzGerald MG; Shimada A; Ishioka C; Kanamaru R; MacDonald DJ; Unsal H; Finkelstein DM; Bowcock A; Isselbacher KJ; Haber DA
    N Engl J Med; 1997 May; 336(20):1416-21. PubMed ID: 9145678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic analyses of male breast cancer in Israel.
    Sverdlov RS; Barshack I; Bar Sade RB; Baruch RG; Hirsh-Yehezkel G; Dagan E; Feinmesser M; Figer A; Friedman E
    Genet Test; 2000; 4(3):313-7. PubMed ID: 11142766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.